The Titan Protocol

Section 120 of 440

APPENDIX AD: PERSONAL SCIENCE & RESPONSIBLE BIOHACKING

This appendix governs Personal Science and responsible biohacking as a cross-cutting method and a source branch within the Titan Research & Governance Lab. The method’s low-risk public status is limited to its declared record contract; it does not create a twenty-fifth Core domain, add an operational capability module, award a capability level or promote an intervention. Personal records cannot promote a Titan claim or change the Operational Standard.

Titan uses responsible biohacking to mean a reversible biological, behavioural, environmental or technological change tested against a declared real-world outcome. The preferred route is the lowest-risk, least-invasive change capable of answering the question. A mechanism, biomarker movement, device score or persuasive story is not enough. Measurement error must remain visible, and null or adverse results remain part of the record. A personal comparison may be indexed or reviewed by the Lab only through the same provenance, evidence, safety and consent rules; a favourable result does not bypass the unified promotion process.

1. PURPOSE, LIMITS AND OPERATING LAW

Personal science can help one person test whether a low-risk, reversible change is associated with a predeclared outcome under specified conditions. It does not by itself establish a diagnosis, prove treatment efficacy, establish causation beyond the design, or show that another person will benefit. It cannot convert a consumer device into a clinical instrument or replace qualified care.

  • Outcome before optimisation. Name the useful function first; choose a measure only after the outcome is clear.
  • Least risk and least invasion. Prefer ordinary environmental or behavioural changes over supplements, devices, procedures or pharmacology when they can answer the same question.
  • One result is not an identity. A result applies to the declared person or configuration, task, context, period and measure.
  • Direct, proxy and biomarker outcomes stay separate. A proxy can inform a decision; it cannot silently inherit the meaning of the real-world outcome.
  • Safety, consent, access and legitimacy outrank signal size. A larger effect obtained by increasing risk, burden, coercion or exclusion is not a better result.
  • Null, contradictory and adverse findings are retained. Selective deletion turns personal science into marketing.
  • Stopping is a valid outcome. New or worsening symptoms, a crossed stop rule, a material interaction concern, or loss of consent ends the experiment and routes the person to appropriate help.

2. FOUR ROUTING CLASSES

The classes below govern what this appendix may describe as a public, self-directed route. They are not capability levels, Core scores, medical risk classifications or permanent status promotions. A topic may move only through a separate, versioned evidence and authority decision.

Operational — bounded public method

Operational here means that Titan can responsibly teach the method or a low-risk route inside the existing safety screen. It does not mean that every personal result is true or that the route treats a health condition.

  • The governed personal-comparison method in this appendix.
  • Wearable and sensor data hygiene: preserving device identity, version, conditions, missingness, uncertainty and claim boundary.
  • Ordinary light and environmental design within normal living conditions: daytime light, darker evenings and sleep periods, ventilation, glare and noise management, comfort and accessible state-transition cues.
  • Personal-data minimisation, local-first handling where feasible, export, deletion, consent and an explicit sharing boundary.

Restricted — qualified or condition-specific route

Restricted items are not public progression protocols. They require an appropriate clinician, regulated service, qualified supervisor or condition-specific pathway, together with the device, product and jurisdiction rules that apply.

  • Clinically indicated continuous glucose monitoring and treatment interpretation.
  • Therapeutic light boxes.
  • Heat or cold beyond ordinary environmental conditions.
  • Clinical neurofeedback.
  • Photobiomodulation for a diagnosed condition.
  • Hyperbaric oxygen therapy.
  • Breath retention, hypoxia or pressure exposure.
  • Restrictive diets, extended fasting or supplement protocols in illness.
  • Medication, hormone or psychoactive-substance changes.
  • Clinical toxicology testing or treatment.

Research Observatory — interesting, incomplete or non-operational

An Observatory entry records a live research question and its limits. It is not a recommendation, a scoreable capability, a treatment route or permission to run a high-risk self-experiment.

  • Healthy-person CGM optimisation.
  • Sauna or passive heat for longevity.
  • Cold exposure for longevity or general resilience.
  • Red-light or photobiomodulation enhancement.
  • General cognitive neurofeedback.
  • Epigenetic-age clocks.
  • Direct-to-consumer microbiome profiling.
  • Grounding or earthing.
  • NAD products, rapamycin and senolytics.
  • Experimental peptides and longevity pharmacology.
  • Psychedelic-assisted capability claims.

Rejected from public instruction or public claim

Rejected means Titan will not present the claim as established or supply a do-it-yourself progression. It does not imply that every underlying phenomenon is impossible; it records that the stated public claim is unsupported, misleading or unsafe.

  • Generic detox programmes or consumer toxin-burden scores.
  • Sauna as proven toxin removal.
  • Public PFAS or microplastic-clearing protocols, including oat beta-glucan as an established PFAS treatment.
  • Smartwatches or smart rings claimed to measure glucose independently without piercing the skin.
  • Readiness scores used as diagnoses or prescriptions.
  • Universal HRV, glucose, sleep or light targets.
  • Do-it-yourself peptides, HBOT, brain stimulation or pharmacological longevity cycles.
  • Consumer microbiome ‘dysbiosis’ diagnoses.
  • Epigenetic age presented as a definitive biological age.
  • Biomarker movement presented as proof of longer life.
  • Grounding presented as proven ATP enhancement.
  • Dopamine hacking or brainwave mastery.

3. THE PERSONAL COMPARISON STANDARD

Use all twelve elements before interpreting a personal experiment. A blank, changed after the result, is not a predeclared plan. Where randomisation or blinding is practical, use it; where it is not, record the limitation rather than pretending it disappeared.

  1. Bounded question. State one question about one feasible change, one declared outcome and one defined person or configuration.
  2. Context and baseline. Record a stable-enough baseline window, ordinary variation, supports, symptoms, schedule and relevant circumstances before changing the principal variable.
  3. One principal change. Hold other important features as steady as practical. If several features change, treat the intervention as a package and do not assign the effect to one component.
  4. Primary outcome and minimum change. Choose the primary outcome in advance and state the smallest change that would matter. Keep that judgement separate from the instrument’s measurement error or minimum detectable change.
  5. Measurement and uncertainty. Name the direct, proxy or biomarker measure; its unit; collection method; expected error; reference method where relevant; and what the measure cannot establish.
  6. Duration, comparison and washout. Predeclare the observation period, comparison condition or counterbalanced order, review date and any washout needed to reduce carryover.
  7. Confounders and adherence. Record material changes in sleep, illness, medication, caffeine, alcohol, menstrual or hormonal context, workload, travel, device use, weather and adherence rather than explaining them away later.
  8. Missing-data rule. Decide before the result how missed readings, device failure, interrupted days, outliers and protocol changes will be handled. Preserve the raw event and reason.
  9. Stop rule and escalation route. State symptoms, thresholds, interactions, adverse events or life circumstances that cause immediate stop, and name the qualified or emergency route to use.
  10. Null and adverse results. Record no detected change, worse outcomes, excess burden, loss of access and unintended effects with the same permanence as a favourable result.
  11. Delayed retest. Where the claim involves a lasting benefit, schedule a delayed result after feedback, novelty or intensive support is removed when safe.
  12. Generalisation boundary. State exactly who, what task, which device or support, which setting and which period the result covers. Do not generalise from one person to a population.

When a personal experiment does not fit

Do not use this method for an urgent or rapidly progressive problem, an irreversible intervention, a rare catastrophic outcome, an experiment that requires stopping known-effective care, or a change whose safe use depends on diagnosis or dose management. Those questions need an appropriate clinical, occupational, research-ethics or other qualified route.

4. WEARABLE AND SENSOR INTEGRITY

A wearable reading is an estimate produced by a particular sensor, device model, firmware, application, algorithm, placement, body and context. Validation of one metric or software version does not validate every output, population, activity or later algorithm. Consumer-wellness classification is not proof of clinical accuracy.

  • Preserve manufacturer, model, sensor location, serial or lot where relevant, firmware, application and algorithm version, sampling interval, units, timestamp and timezone.
  • Preserve the reference method, validation population and context. A resting heart-rate result does not validate energy expenditure, sleep stages or arrhythmia detection.
  • Record fit, placement, skin contact, movement, temperature, charging, connectivity, missingness, manual edits and vendor-side changes.
  • Keep raw observations where lawful and practical. Do not overwrite a prior value because the device later recalculated a score.
  • Compare change with expected error and normal within-person variation. A visually different graph may still be inside the noise.
  • Keep assisted and unaided results separate. A device-supported result belongs to the configured person-device system.
  • Do not use a consumer device alone to diagnose, exclude disease, change medication or decide that a concerning symptom is safe.

Glucose requires an explicit distinction. An authorised CGM uses a sensor inserted through the skin to estimate interstitial glucose and should be used within its indication and qualified treatment pathway. A watch may display data from such a device; that does not make the watch a non-invasive glucose sensor. Healthy-person optimisation remains an Observatory question. The FDA states that it has not authorised, cleared or approved any smartwatch or smart ring intended to independently measure or estimate blood glucose without piercing the skin; Titan rejects those products as a public measurement route.

Primary-source anchors: 536-night wearable validation record, https://pubmed.ncbi.nlm.nih.gov/40834291/ ; FDA non-invasive glucose safety communication, https://www.fda.gov/medical-devices/safety-communications/do-not-use-smartwatches-or-smart-rings-measure-blood-glucose-levels-fda-safety-communication

5. LIGHT AND ORDINARY ENVIRONMENTAL EXPOSURE

Light is a time cue, not a neurotransmitter hack. For many healthy adults on a daytime schedule, a stable pattern of more light during the day, much less light in the hours before sleep, and darkness during sleep can support circadian timing. Response depends on timing, duration, spectrum, prior light history, age, schedule, vision, medication and individual sensitivity.

The CIE position statement describes higher daytime exposure, lower exposure in the three hours before bed and near-darkness during sleep as general guidance developed principally for healthy young adults. Its research benchmarks are not universal prescriptions and do not automatically apply to children, older adults, shift workers, people with eye or mood conditions, or therapeutic light treatment.

  • Use ordinary daylight or well-designed indoor light without staring at the sun, seeking UV exposure or treating brightness as a contest.
  • Reduce evening glare and unnecessary brightness when feasible; preserve safe navigation, accessibility, caregiving and work needs.
  • Treat therapeutic light boxes as Restricted. Timing, intensity and health context can matter, including for people with eye disease, photosensitising medication or bipolar-spectrum risk.
  • Environmental design may also test ventilation, noise reduction, thermal comfort, clutter, cue visibility or a state-transition ritual against a declared functional outcome.
  • Do not claim that sound frequencies, cinematic environments, light colours or other sensory inputs reliably ‘hack dopamine’ or force flow, recovery or autonomic states on command.

Primary source: CIE PS 001:2024, https://www.cie.co.at/publications/cie-position-statement-integrative-lighting-recommending-proper-light-proper-time-3rd

6. THE BIOHACK EVIDENCE CARD

Every public biohack record should carry one compact, versioned evidence card. A blank field remains unknown; it is not completed by inference. The card must include:

  • Record identity, version, date, owner and change history.
  • Exact claim and explicit non-claims; allowed public wording and prohibited wording.
  • Capability locus and execution configuration, including human-only, supported or person-device operation.
  • Population, inclusion and exclusion boundaries, setting and relevant context.
  • Declared real-world outcome, primary measure and whether each endpoint is direct performance, proxy, symptom report or biomarker.
  • Intervention or exposure, dose or duration where relevant, comparison, adherence, washout and delayed-retest plan.
  • Device, sensor, assay, product, software and algorithm version; reference method; measurement error; missing-data rule.
  • Evidence design, source identities, effect estimate, uncertainty, replication, retention, transfer and negative or contradictory evidence.
  • Cost, time, attention, accessibility, environmental and opportunity burden.
  • Known and plausible risks, contraindications, interactions, supervision requirement, stop rule and escalation route.
  • Privacy, data controller, storage, sharing, vendor access, export, deletion and model-training boundary.
  • Current routing class, rationale, unresolved question, next evidence required and the authority able to change the class.

7. CORRECTIONS TO ATTRACTIVE CLAIMS

PFAS, microplastics and ‘detox’

Titan does not provide a public PFAS- or microplastic-clearance protocol. Current ATSDR clinical guidance emphasises identifying and reducing ongoing exposure and using ordinary risk-based care. A PFAS blood result does not predict an individual’s future illness and does not by itself identify a treatment. There is no established do-it-yourself route to remove PFAS from the body.

The 2025 oat beta-glucan/PFAS paper was a short secondary analysis of stored serum from 72 adult men in a parent cholesterol trial, not a trial designed to establish PFAS treatment. Total PFAS declined in both oat and rice-control groups without a between-group difference in magnitude; a selected PFAS sum fell significantly only within the oat group. The authors called for larger, longer dedicated trials. Titan therefore keeps the fibre-PFAS hypothesis in the Observatory and prohibits wording that one gram of oat beta-glucan before meals ‘clears PFAS’ or ‘detoxes forever chemicals’.

Reducing a verified exposure source may be sensible; that is not the same as clearing a body burden. Do not self-prescribe chelation, plasmapheresis, blood donation, sauna, drugs or supplements as PFAS removal. Clinical toxicology questions belong with qualified environmental or occupational health services.

Sources: ATSDR clinician guidance, https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/clinical-evaluation-management.html ; 2025 oat beta-glucan secondary analysis, https://link.springer.com/article/10.1186/s12940-025-01165-8

Grounding or earthing

Grounding remains in the Research Observatory. Small pilot studies report selected subjective or physiological changes, but the literature is small, heterogeneous and not independently replicated at a level that establishes reliable clinical benefit or the proposed electron-transfer mechanism. Titan does not claim that grounding increases mitochondrial ATP, reduces reactive oxygen species, resets cortisol, accelerates athletic recovery or treats disease.

Walking outdoors or barefoot may be enjoyable and can add movement or nature contact, but any benefit cannot be attributed to electrical grounding from the current evidence. Titan does not endorse grounding products or improvised electrical connections.

Boundary sources: early narrative review, https://doi.org/10.1155/2012/291541 ; small occupational randomised study, https://pubmed.ncbi.nlm.nih.gov/30448083/

Heat, cold and longevity

Passive-heat and cold-exposure studies can investigate bounded physiological or symptom outcomes. They do not establish a public longevity prescription or universal resilience effect. Heat and cold beyond ordinary environmental conditions remain Restricted because fainting, burns, cold injury, arrhythmia, medication effects and other risks depend on the person and protocol. Sources: passive heat, https://pubmed.ncbi.nlm.nih.gov/41049507/ ; cold exposure, https://pubmed.ncbi.nlm.nih.gov/35068365/

Photobiomodulation and neurofeedback

A condition-specific pilot or a task-specific feedback effect does not establish healthy-person enhancement. Photobiomodulation for a diagnosed condition and clinical neurofeedback remain Restricted; red-light enhancement and general cognitive neurofeedback remain Observatory topics. Titan rejects ‘brainwave mastery’. Sources: photobiomodulation pilot, https://pubmed.ncbi.nlm.nih.gov/41768981/ ; neurofeedback evidence record, https://pubmed.ncbi.nlm.nih.gov/42324882/

Epigenetic clocks and microbiome profiles

An epigenetic clock is a model-derived biomarker, not a definitive biological age or proof that a person will live longer. A direct-to-consumer microbiome report is method-, pipeline- and database-dependent and cannot by itself diagnose ‘dysbiosis’ or prescribe a diet or supplement. Both remain Observatory topics. Sources: epigenetic-clock evidence record, https://pubmed.ncbi.nlm.nih.gov/36277076/ ; direct-to-consumer analytical performance study, https://www.nature.com/articles/s42003-025-09301-3

HBOT, peptides and pharmacological longevity

HBOT is a regulated pressure-and-oxygen treatment, not a wellness chamber progression. The FDA has reported serious injuries and deaths and stresses trained staff, patient monitoring, fire prevention, maintenance and manufacturer instructions. Experimental peptides, NAD products, rapamycin, senolytics and other longevity pharmacology do not become safe or effective because they are sold online or described as research compounds. Titan supplies no do-it-yourself cycle.

Sources: FDA HBOT safety letter, https://www.fda.gov/medical-devices/letters-health-care-providers/follow-instructions-safe-use-hyperbaric-oxygen-therapy-devices-letter-health-care-providers ; FDA compounded-substance risk list, https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

8. PRIVACY, ACCESS AND LEGITIMACY

  • Collect only what the declared question needs. More intimate data is not automatically better evidence.
  • Prefer local-first storage where feasible; identify every vendor or human who can access the record and whether data may be reused for advertising or model training.
  • Provide export, deletion and withdrawal routes. A person may stop tracking without losing access to ordinary support or care.
  • Treat disability-led, assisted and culturally situated routes as valid configurations. Do not require a standard body, schedule, diet, device or household.
  • Do not publish another person’s health or sensor data, infer consent from participation, or use workplace and insurance power to coerce tracking.
  • Commercial sponsorship, affiliate payment, popularity and a dramatic personal result do not change the evidence class.

9. CLOSING THE LOOP

At the review point, compare the declared outcome with baseline, the comparison condition, expected measurement error, burden, missingness and the stop rule. Record one of four human decisions: keep, adapt, pause or retire. The system may display the evidence; it does not choose automatically.

A favourable proxy with no meaningful functional benefit is not success. A small benefit may still be worthwhile if burden is low and the person values it. A statistically or visually noticeable change can still be unimportant. A null or adverse result is useful evidence when it prevents repetition of an unhelpful or unsafe route.

New symptoms, clinically concerning measurements, medication questions or a crossed safety boundary should be taken to an appropriate professional. Do not delay urgent help to complete an experiment or preserve a clean dataset.

10. PRIMARY SOURCE LEDGER

Sources were checked for this candidate on 3 August 2026. Each source supports only the bounded use stated in this appendix; a citation is not personal clearance, evidence of universal benefit or automatic status promotion.

Appendix status: cross-cutting Methods layer and Lab source branch. Frozen Core effect: none. Operational-module effect: none. Capability-status effect: none. The Research Observatory and Restricted routes retain their existing governance requirements. The Lab master register may preserve and route Personal Science records, but consolidation does not change their evidence class or operational authority.